Multicenter, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intramyocardial Injection of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart Failure (NYHA Class III-IV)
Latest Information Update: 07 Apr 2026
At a glance
- Drugs HiCM 188 (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Sponsors Help Therapeutics
Most Recent Events
- 03 Apr 2026 Status changed from not yet recruiting to recruiting.
- 01 Apr 2026 New trial record